We’ve just been named Startup Spotlight 2025 winner at ChinaBio in Shanghai — sponsored by Pfizer — for our novel RNA therapeutic BA-R166!

Why BAR-166? Because it’s cheap (vaccine-level cost), fast (works in 3 days) and safe (locally administered). Designed for all patients with early-stage cancer, right after diagnosis and before surgery. We believe this kind of rapid, interventional immunotherapy can become the fourth pillar of oncology, reducing the need for life-limiting surgeries in the future.

Massive thanks to the judges — Anthony Barry (Pfizer), Tam C. Nguyen (St Vincent's / Horizon 3 Healthcare), and Jia Zhuang, Ph.D. (ATLATL Innovation Center) — and to EBD Group and ATLATL Innovation Center for the generous prize that will help us accelerate development in China. And to the brilliant international finalists working across ADCs, AI-synbio, neuropsychiatry and beyond.